PHARMACEUTICAL 2013 - Optimal capacity planning and resource allocation for a portfolio of clinical trials
View: 527
Website https://compliance2go.com |
Edit Freely
Category PHARMACEUTICAL 2013
Deadline: June 20, 2013 | Date: June 20, 2013
Venue/Country: Online, U.S.A
Updated: 2013-05-03 18:05:17 (GMT+9)
Call For Papers - CFP
Why you should attendTo become familiar with newest development in optimal capacity planning and resource allocation for a portfolio of clinical trialsDescription of the topicEfficient strategic capacity planning and resource allocation is becoming a hot topic for biopharmaceutical companies and Clinical Research Organizations (CRO) due to increasing pressure to reduce cost of drug development. It is critical for many clinical organizations to find a better approach to increase effectiveness in resource capacity planning, especially for portfolio of clinical trials.When biopharmaceutical company plans to start new trials, optimal capacity planning solution means: (1) optimal resource utilization; (2) optimal resource allocation between ongoing and new trials; (3) optimal outsourcing strategy; (3) identification of resource bottleneck; (4) optimal scheduling of new trials; (5) optimal hiring and budget allocation strategy for a variety of employee roles, and (6) understaffing risk assessment.Effective strategic capacity planning for CRO means optimal trials “throughput”, and their allocation across therapeutic areas, and stages of development.Both types of organizations experience significant challenges related to resource reallocation due to trial cancellation or invocation of a new trial.ORBee Consulting developed powerful decision making methodology based on rigorous mathematical models for optimal capacity planning and resource allocation in clinical research. Our technique saves money (up to 30%) by uncovering better resource allocation solutions.Areas Covered In the SeminarWhat you will learn: How to apply optimization technology to capacity planning in biopharmaHow to derive workload demand and supply (overview) on a role levelHow to optimize capacity planning and resource allocation across portfolio of clinical trials for both biopharma companies and CROs.How to identify resource bottleneck using optimization toolsHow to reallocate resources due to inclusion or cancellation of clinical trialsHow to calculate understaffing riskWho will benefitBiopharmaceutical companies, CROs, consulting companiesPortfolio managersBusiness analystsBusiness Development analystsProject managersFinancial analystsResource plannersExecutive managementAbout SpeakerVladimir Shnaydman, Ph.D, ORBee Consulting, President (2004 ? current). The company’ focus is design and development of analytical tools and techniques for optimization of business solutions for life science industries. Company also provides consulting service, utilizing capabilities of developed tools and techniques. Vladimir has BS & MS Electrical Engineering & Computer Science, MS in Applied Mathematics & Operations Research, and Ph.D. in Engineering. He contributed to many industries such as biotechnology, computer networking, data storages, water resources planning and management, telecommunications, transportation, and others. Dr. Shnaydman published more than 50 papers. He is co-author of three books.Speaker : Dr Vladimir ShnaydmanProduct ID : F62324Schedule Date :Thursday, June 20, 2013duration : 12:30 to 01:30 PM EDThttps://compliance2go.com/index.php?option=com_training&speakerkey=62&productKey=250
Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.